Cytek Biosciences, Inc. CTKB Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s other commercial liabilities?
- Cytek Biosciences, Inc. (CTKB) reported other commercial liabilities of $19.78M in Q1 2026.
- How has Cytek Biosciences, Inc.'s other commercial liabilities changed year-over-year?
- Cytek Biosciences, Inc.'s other commercial liabilities increased by 3.0% year-over-year, from $19.2M to $19.78M.
- What is the long-term trend for Cytek Biosciences, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Cytek Biosciences, Inc.'s other commercial liabilities has grown at a 20.9% compound annual growth rate (CAGR), from $9.05M to $23.42M.